Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
2.190
-0.370 (-14.45%)
At close: Apr 7, 2026, 4:00 PM EDT
2.360
+0.170 (7.76%)
After-hours: Apr 7, 2026, 7:54 PM EDT

Galectin Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
5.85.865.946.626.36
Research & Development
14.2936.5732.1331.7423.82
Total Operating Expenses
20.0942.4338.0738.3530.18
Operating Income
-20.09-42.43-38.07-38.35-30.18
Interest Income
0.130.340.230.050
Interest Expense
-7.33-5.54-2.79-1.03-0.49
Other Non-Operating Income (Expense)
-3.550.59-0.430.560.14
Total Non-Operating Income (Expense)
-10.75-4.61-2.99-0.42-0.35
Pretax Income
-30.84-47.05-41.07-38.78-30.53
Net Income
-30.97-47.2-44.81-38.87-30.7
Net Income Attributable to Preferred Dividends
0.140.153.740.10.17
Net Income to Common
-30.97-47.2-44.81-38.87-30.7
Shares Outstanding (Basic)
6462605959
Shares Outstanding (Diluted)
6462605959
Shares Change (YoY)
2.56%3.57%1.29%1.48%2.63%
EPS (Basic)
-0.48-0.76-0.74-0.65-0.52
EPS (Diluted)
-0.48-0.76-0.74-0.65-0.52
Shares Outstanding
65.263.1661.8559.4359.34
Free Cash Flow
-23.88-41.77-32.97-31.06-24.31
Free Cash Flow Per Share
-0.37-0.67-0.55-0.52-0.42
EBITDA
-20.03-42.4-38.04-38.32-30.14
EBIT
-20.09-42.43-38.07-38.35-30.18
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q